Your browser doesn't support javascript.
loading
Graft failure after "ex-vivo" T-cell depleted haploidentical transplantation in pediatric patients with high-risk hematological malignancies. A risk factors and outcomes analysis.
Diaz, Miguel A; Lopez, Ivan; Molina, Blanca; Pereto, Alba; Zubicaray, Josune; Sevilla, Julian; Castillo, Ana; Alenda, Raquel; Moreno, Miguel A; Vicario, Jose Luis; González-Vicent, Marta.
Afiliación
  • Diaz MA; Department of Pediatrics, Hematopoietic Stem Cell Transplantation and Cellular Therapy Unit, Hospital Infantil Universitario "Niño Jesus", Madrid, Spain.
  • Lopez I; Department of Pediatrics, Hematopoietic Stem Cell Transplantation and Cellular Therapy Unit, Hospital Infantil Universitario "Niño Jesus", Madrid, Spain.
  • Molina B; Department of Pediatrics, Hematopoietic Stem Cell Transplantation and Cellular Therapy Unit, Hospital Infantil Universitario "Niño Jesus", Madrid, Spain.
  • Pereto A; Department of Pediatrics, Hematopoietic Stem Cell Transplantation and Cellular Therapy Unit, Hospital Infantil Universitario "Niño Jesus", Madrid, Spain.
  • Zubicaray J; Division of Hematology, Blood Bank and Graft Manipulation Unit, Hospital Infantil Universitario "Niño Jesus", Madrid, Spain.
  • Sevilla J; Division of Hematology, Blood Bank and Graft Manipulation Unit, Hospital Infantil Universitario "Niño Jesus", Madrid, Spain.
  • Castillo A; Oncology/Hematology Lab, Hospital Infantil Universitario "Niño Jesus", Madrid, Spain.
  • Alenda R; Histocompatibility Lab, Community Transfusion Center of Madrid, Madrid, Spain.
  • Moreno MA; Histocompatibility Lab, Community Transfusion Center of Madrid, Madrid, Spain.
  • Vicario JL; Histocompatibility Lab, Community Transfusion Center of Madrid, Madrid, Spain.
  • González-Vicent M; Department of Pediatrics, Hematopoietic Stem Cell Transplantation and Cellular Therapy Unit, Hospital Infantil Universitario "Niño Jesus", Madrid, Spain.
Leuk Lymphoma ; 62(13): 3130-3137, 2021 12.
Article en En | MEDLINE | ID: mdl-34263704
ABSTRACT
Risk factors and outcomes of GF after TCD haploidentical transplantation in children with hematological malignancies were analyzed. 148 TCD transplants were included. 78 patients were diagnosed of ALL and 70 patients of AML. 22 out of 148 patients developed GF. MVA showed that patient <9 years (HR 5.0; 95% CI 1.1-23.0; p = 0.03) and pre-transplant CD8+ ≥150/µL (HR 12.0; 95% CI 1.6-95.3; p = 0.01) were associated with GF. A score was assigned to each patient. The cumulative incidence of GF for patients with CD8+ ≥150/µL (2 points) was 6 ± 4% and 3 ± 2% for patients <9 years (1 point) while for patients with 3 points was 24 ± 6%, With a median follow-up of 48 months (range; 4-180 months), 14 (64%) of 22 patients with GF are alive and disease-free. DFS for GF patients was 53 ± 12%. In conclusion, patient age and pre-transplant CD3+/CD8+ are associated with GF in children undergoing TCD haploidentical transplantation.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas / Enfermedad Injerto contra Huésped Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas / Enfermedad Injerto contra Huésped Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: España